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ABSTRACT
Despite limited research supporting its benefits, adults in the United States commonly use
herbal forms of complementary and alternative medicine (CAM) such as cannabidiol
(CBD) for anxiety. Little is known about the treatment-related beliefs that may motivate
their choice to use CAM. The present study used mixed methods to assess differences in
CAM-related treatment beliefs in a sample of adults with generalized anxiety. For a
cross-sectional online survey hosted via Research Electronic Data Capture (REDCap),
180 adults were recruited. Generalized anxiety symptoms and severity were assessed
using the Generalized Anxiety Disorder 7 (GAD-7) screener. Beliefs about CAM were
measured through the Complementary and Alternative Medicine Beliefs Inventory
(CAMBI) and Holistic Complementary and Alternative Medicine Questionnaire
(HCAMQ). An open-ended prompt and text box captured perceptions about perceived
benefits and harms associated with CBD’s relationship to cannabis. Independent samples
t-tests were conducted for groups of CBD and non-CBD users endorsing anxiety to
compare mean scores on the HCAMQ and CAMBI subscales. CBD users endorsed
higher ratings of anxiety severity (p < .001) and beliefs in natural treatment (p = .002).
The results of this study suggested that CBD users may place greater importance on
treatment-related beliefs about naturalness than non-users. Future evaluations of
treatment-related beliefs in CBD users as well as traditional provider approaches to
integrative models of care are needed to better understand how such beliefs impact use
behaviors.
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CHAPTER 1: INTRODUCTION
Statement of the Problem
Complementary and alternative medicine (CAM) is a term referring to treatment
approaches considered as beyond the purview of conventional or orthodox medicine in
the United States (Bishop et al., 2006, 2007; Ding et al., 2018). CAM use seems
prevalent in the United States, where mental healthcare providers might benefit from
clarifying their knowledge of CAM and presenting more accurate information to the
utilizers they treat (Bassman & Uellendahl, 2003; Jou & Johnson, 2016). Dialogues
between providers and CAM users require a greater awareness on the part of providers of
what motivates the choice to use CAM. Demographics, CAM type, and beliefs about
illness and treatment are factors associated with CAM usage (Bishop et al., 2006, 2007).
Natural products have had the highest utilization rates by adults in the United
States relative to other types of CAM (Clarke et al., 2015). Adults who endorse anxiety
are among the top consumers of natural products (Nahin et al., 2009; Purohit et al., 2015).
Anxiety is highly prevalent in the general population and the top psychological condition
treated by CAM users in the United States, with an estimated one in five American adults
using an herbal form of CAM to manage an anxiety disorder (Barnes et al., 2008;
Bystritsky et al., 2012; Kessler et al., 2012). Certain demographic factors (e.g., higher
education, identifying as female) have predicted CAM use for anxiety, as well as beliefs
in holistic health, natural treatments, and self-management of health (McIntyre, Saliba, &
Moran, 2015; McIntyre, Saliba, Wiener, et al., 2015). Those diagnosed with generalized
anxiety disorder (GAD) are among the highest utilizers of CAM for anxiety (Ravven et
al., 2011). Individuals experiencing GAD and CAM users with anxiety have analogous
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treatment concerns, such as clinically significant perceptions of control over worry,
according to criteria from the Diagnostic and Statistical Manual of Mental Disorders (5th
ed.; DSM-5; American Psychiatric Association, 2013).
In herbal medicine, cannabidiol products represent one of the strongest markets in
recent years (BDS Analytics, 2019). Cannabidiol (CBD), a naturally occurring
cannabinoid found in Cannabis, is a compound found in several over-the-counter
products sold throughout the United States (VanDolah et al., 2019). An estimated 14% of
Americans currently use CBD products (Gallup, 2019). CBD has gradually acquired
popularity and repute as a treatment for various illnesses due to its purported medical
benefits and lack of intoxicating effects found in other cannabinoids such as
tetrahydrocannabinol (THC; Corroon & Phillips, 2018; Schoedel et al., 2018;
Soleymanpour et al., 2021; VanDolah et al., 2019). It is a proposed treatment for
numerous mental disorders and physical conditions (White, 2019). However, the only
clinical application for CBD approved by the U.S. Food and Drug Administration (FDA)
to date is for the treatment of pediatric seizures (United States Food and Drug
Administration [USFDA], 2020b). According to existing clinical trials and information
on the safety profile of CBD, users have had negative health effects that would prohibit
federal approval for clinical use (Bonaccorso et al., 2019; Brown & Winterstein, 2019;
Taylor et al., 2019).
Given the lack of empirical support for and increasing public interest in its
applications, CBD may be categorized as a form of herbal medicine and considered as
CAM. For mental healthcare practitioners, this label lends a framework for understanding
how and why individuals may choose to use CBD. Preliminary research exists on factors
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associated with CAM use (i.e., demographics and form of CAM via CBD) in CBD-using
populations. According to an anonymous online survey of users principally residing in
the United States, anxiety is the most treated psychological condition and third most
treated health condition overall in CBD-using adults (Corroon & Phillips, 2018). In an
American poll of consumption habits, 20% of CBD users reported primarily using it in
the self-treatment of anxiety (Gallup, 2019). Some clinical research suggests that CBD
has anxiolytic properties, though the power and number of studies remain limited
(Bonaccorso et al., 2019). In the absence of empirical support for CBD as a form of
conventional medicine, motivations for CBD use in adults who have generalized anxiety
may be identified through treatment-related beliefs as a predictive factor for CAM use.
Treatment and illness-related beliefs, as well as other factors that are predictive of
CAM use may be understood collectively using the Common-Sense Model of SelfRegulation (CSM) as applied to health-related behavior (Leventhal et al., 2016). The
CSM assumes that environmental cues and personal experiences interact with cognitivebehavioral processes related to illness in a reciprocal, dynamic manner. The model
organizes potential motivations for CAM use such as perceived control over illness and
treatment, using experiential information to support positive beliefs about CAM, or trying
a novel treatment gaining public attention (i.e., adhering to a subjective norm; Bishop et
al., 2007). In the context of the CSM, domains of treatment-related beliefs about CAM
previously associated with the decision to use it (i.e., naturalness, scientific validity,
holistic health characteristics, participation in treatment) may be considered as mutually
influential on the decision to use CAM.
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The efficacy of CBD as a form of CAM for anxiety remains unknown despite its
common usage in the United States. Its common use and over-the-counter level of access
may create competition with therapeutic and pharmacological evidence-based treatments
for anxiety that results in opportunity costs for practitioners and users (Bandelow et al.,
2017). CBD users may hold treatment beliefs about CAM that predict the choice to use it
as an alternative or adjunctive therapy for anxiety. At the time of this review, no research
was found concerning the state of treatment beliefs about CAM for adults who have
experienced anxiety and choose CBD as a form of CAM as treatment in the United
States. A study of treatment-related beliefs about CAM for adults who experience anxiety
and use CBD serves to increase awareness of beliefs that may influence the choice to use
CBD as CAM in an understudied but emergent population.
Purpose of the Study
The present study used mixed methods to assess information about treatment
beliefs related to CAM endorsed by both CBD-using and non-using individuals with
generalized anxiety. An anonymous web-based cross-sectional survey captured
demographic characteristics relevant to CBD users as well as non-using individuals with
generalized anxiety. A screening tool based on core symptoms of GAD (i.e., the GAD-7)
determined the presence of clinically significant anxiety symptom severity levels.
Existing measures of CAM-related beliefs (i.e., the CAMBI and HCAMQ) were used to
represent relevant beliefs towards using CBD as a form of CAM. Respondents answered
an exploratory question regarding their beliefs about CBD’s relationship to cannabis as
these beliefs might pertain to the choice to use CBD. This furthered research on the topic
of CBD use and characteristics of its users as data on this growing population remain
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limited despite an identified need for best practices in working with CAM users in
clinical settings.
Research Questions and Hypotheses
1. What types of CAM-related treatment beliefs distinguish individuals using
cannabidiol to manage generalized anxiety from conventional medicine users?
Hypothesis I: Individuals who choose CBD will have significantly higher scores on a
measure of beliefs in the scientific validity of CAM relative to non-CBD users.
Hypothesis II: Individuals who choose CBD will have significantly higher scores on a
measure of beliefs in the holistic properties of CAM relative to non-CBD users.
Hypothesis III: Individuals who choose CBD will have significantly higher scores on
a measure of beliefs in natural treatment via CAM relative to non-CBD users.
Hypothesis IV: Individuals who choose CBD will have significantly higher scores on
a measure of involvement in treatment relative to non-CBD users.
2. What beliefs do CBD users endorse regarding CBD’s relationship to cannabis?
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CHAPTER 2: REVIEW OF THE LITERATURE
In the United States, an estimated 38 million adults did not use conventional
healthcare during the previous year and 38% of them had an identifiable health need
(Nahin et al., 2010). Approximately 1 in 4 non-utilizers of conventional healthcare used a
form of alternative medicine to address their health needs. These trends point toward an
opportunity cost for evidence-based approaches in healthcare, as well as inefficient
dialogues between healthcare professionals and non-utilizers about treatment. Though
rapport between these parties could be improved by addressing the factors associated
with choosing alternative medicine over conventional healthcare, mental health
practitioners may favor tacit agreement with their clients’ use of alternatives to
conventional treatment and forego discussions of risk and harm (Bassman & Uellendahl,
2003; Gallup, 2019; Nahin et al., 2010).
Psychologists have cited mostly anecdotal evidence for their esteemed expertise
in alternative forms of medicine, some of which are offered at the exclusion of evidencebased methods (Bassman & Uellendahl, 2003). For common psychological conditions
such as anxiety disorders, alternative forms of treatment present both an opportunity cost
and the potential for harm as there is greater evidentiary basis for the use of beneficial,
low-risk treatments like cognitive-behavioral therapy (Bandelow et al., 2017). Once a
treatment relationship is initiated with a patient, informed consent (e.g., safety, informed
decision-making, quality of empirical support) and professional competency (i.e.,
reasonable care, negligence claims, training format and duration, knowledge of
area/technique of interest) concerns must be addressed whether a provider offers
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alternative therapies or not (Bassman & Uellendahl, 2003; Knapp et al., 2017).
Psychologists and others who offer therapeutic services could increase their commitment
to professional ethics and improve their understanding of relevant risks by preemptively
educating themselves on complementary and alternative therapies, as well as the
knowledge, beliefs, and attitudes of their patients on these topics.
Natural products are the most used form of adjunctive or alternative medicine
(Clarke et al., 2015). Natural products include dietary and nutritional supplements in
edible, vaporized, or topical forms. Among currently expanding markets in the United
States for natural products is the sale of cannabidiol (CBD), a cannabis plant derivative.
Since 2014, CBD product sales have grown at a faster rate than general sales in cannabis
dispensaries (BDS Analytics, 2019). CBD-only products may appeal to non-cannabis
users as well given that 44% of CBD users do not agree with the legalization of cannabis
and 1 in 10 do not believe marijuana has medical benefits (BDS Analytics, 2019). Being
informed about current trends of what alternative treatments are consumed and how
consumption takes place reasonably improves mental healthcare practitioners’
competency in addressing the clinical needs of patients who use them. The identification
of objective and subjective influences on the rise of CBD in the alternative therapies
market and for the overall usage of natural therapies clarifies why these trends have
occurred. For the current study, an evidentiary basis for and against CBD’s clinical use,
as well as substantiation for an investigation into treatment-related beliefs of adults with
generalized anxiety who use alternative therapies has been provided for this purpose.
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Complementary and Alternative Medicine
Complementary and alternative medicine (CAM) is a categorical label used to
describe approaches to healthcare not included in conventional practice (National Center
for Complementary and Integrative Health [NCCIH], 2018). An approach is regarded as
complementary when used adjunctively with other forms of conventional medicine,
alternative if it is used in the absence of other conventional approaches, and integrative if
coordinated between providers and patients (NCCIH, 2018). Additional specifiers that
have been proposed are whether the approaches are safe or effective, evidence-based, and
if they focus on primary (i.e., preventative) care as well as a holistic (i.e., whole person)
approach to treatment (Ng et al., 2016). Though CAM users in the United States have
expressed public interest in integrative and complementary approaches to medicine,
CAM use is rarely queried by providers and over 42% of patients who use CAM do not
disclose it to providers (Jou & Johnson, 2016). Reasons for non-disclosure include patient
perceptions that providers should ask about CAM use or that reporting their use is
unimportant for the scope of practice. In the interests of coordinating care and risk
management, research on predictors for CAM use has identified areas of focus for
facilitating discussions with CAM users about their behavior. Predictive factors for CAM
use include user demographics and beliefs about treatment and illness, with the preferred
form of CAM being significantly associated with both factors (Bishop et al., 2006).
Demographics Associated with CAM Use
The market for CAM in the United States is robust, with an estimated 33.9 billion
United States dollars (USD) spent by adults on CAM in the United States in 2007 alone
(Nahin et al., 2009). Nearly 40% of adults in the United States are estimated to be CAM
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users, a rate that has gradually increased in the population since the 1990s (Barnes et al.,
2008; Eisenberg et al., 1998; Committee on the Use of Complementary and Alternative
Medicine by the American Public, 2005). CAM use is commonly endorsed by White
women between the ages of 30 and 70, particularly those who endorse higher levels of
education and income (Bishop et al., 2006; Committee on the Use of Complementary and
Alternative Medicine by the American Public, 2005; Green et al., 2017). Forms of
musculoskeletal pain are the most endorsed reasons for using CAM overall, while anxiety
is the most treated psychological condition via CAM (Barnes et al., 2008). According to
national survey data, 37% of adults with 1 or more symptoms associated with a mental
disorder spent significantly greater out-of-pocket amounts on CAM therapies relative to
others, particularly for symptoms of hypersomnia and anxiety (Purohit et al., 2015).
Operationalizing Anxiety
Clinically significant anxiety is commonly represented in the form of anxiety
disorders, which are mental disorders marked by disproportionate fear and anxiety that
may be expressed through behavioral means (American Psychiatric Association, 2013).
Fear is an emotion paired with neurobiological events and survival-based behaviors,
whereas anxiety is an anticipatory mixture of cognitive-affective responses marked by
strong negative affect, perceived lack of control over potential threats, and a state of
intense self-focus (American Psychiatric Association, 2013; Barlow, 2016; Leahy et al.,
2012). Experiences of apprehension differentiate anxiety from fear, as well as the level of
organization and consistency found in the affective response of fear (Barlow, 2016). In
Barlow’s model of anxious apprehension, increasingly intense responses such as worry
become associated with sensory cues (e.g., physiological arousal, visual stimulus, a loud
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sound), leading to a narrower perceptual focus and a greater potential for behavioral
dysfunction (e.g., avoidance responses, lack of concentration).
Anxiety Disorders and CAM
Greater usage of complementary or alternative forms of CAM for anxiety
disorders occurs in higher income countries like the United States, especially in the
treatment of severe anxiety symptoms (de Jonge et al., 2018). This may be partially
attributed to the high prevalence rate of anxiety disorders in the United States, with
approximately 1 in 3 individuals having one or more in their lifetime (Kessler et al.,
2012). Undertreatment and underreporting are common for these conditions and the
actual prevalence rate may be higher (Bandelow & Michaelis, 2015). Diagnosed anxiety
disorders have leading demographics like those observed for individuals who use CAM
as treatment (i.e., White women in adulthood), which are consistent with those found in
cases of generalized anxiety disorder (GAD) as well (American Psychiatric Association,
2013; Asnaani et al., 2010; Bandelow & Michaelis, 2015; Upchurch & Rainisch, 2015).
Generalized Anxiety Disorder and CAM. Generalized anxiety disorder (GAD)
is a form of anxiety disorder marked by excessive anxiety and worry, secondary
symptoms associated with anxiety (e.g., restlessness, fatiguing easily, irritability), and a
limited sense of control over these experiences (American Psychiatric Association, 2013).
In contrast to other anxiety disorders, GAD names worry as a core feature of anxiety and
is broadly representative of anxiety in the form of cognitive-affective symptoms
(American Psychiatric Association, 2013; Barlow, 2015; Crocq, 2017; Leahy et al.,
2012). GAD is less prevalent than other anxiety disorders with a 12-month prevalence
rate of approximately 2.9% and 9% lifetime morbid risk (American Psychiatric
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Association, 2013; Kessler et al., 2012). This disorder has been linked to underutilization
of conventional treatment resources, delays in treatment-seeking, and later age of onset at
the median age of 31 (Bandelow & Michaelis, 2015). GAD is also associated with greater
usage of CAM as a form of mental health treatment. Of the estimated 1 in 25 adults in the
United States using herbal remedies for anxiety or other emotion regulation, those
diagnosed with GAD through structured interviews are the highest utilizers of herbal
forms of CAM for these reasons (Ravven et al., 2011). At nearly 13%, their rate of CAM
use for symptom management is significantly higher than non-diagnosed individuals and
those diagnosed with other anxiety disorders (Ravven et al., 2011).
Type of CAM Usage
A factor previously associated with the decision to use CAM was the type of
CAM being used (Bishop et al., 2006). Though CAM type is not an independent
predictor of CAM use, it is significantly associated with established predictors such as
illness and treatment-related beliefs in addition to demographic variables that are
predictive of the decision to use CAM (Bishop et al., 2006; Bishop et al., 2007).
Understanding the relative strength of personal beliefs about treatment and illness in the
specific context of clinical support and cautions for using certain types of CAM
distinguishes relevant influences in the initiation and maintenance of CAM usage.
Types of CAM fall in general categories of natural products, such as vitamins or
other dietary supplements, and mind-body practices like acupuncture or hypnotherapy
(NCCIH, 2018). Natural products are the most utilized form of CAM by adults in the
United States (Clarke et al., 2015). Herbal supplements are a common and enduring type
of natural product with estimates of national use between 18% and 25% (Peregoy et al.,
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2014; Wu et al., 2011). Herbal supplements are defined by the FDA as orally consumed,
herb-based products labeled as dietary supplements, though the term is also used to refer
to topical products and distillates (Johns Hopkins Medicine, 2019; NCCIH, 2020). The
definition of what constitutes an herbal supplement accommodates products such as
cannabidiol based on several complex clinical, legal, and economic considerations.
Cannabis and Cannabidiol
The third most-used psychoactive substance in the United States is cannabis,
colloquially known as marijuana (Carliner et al., 2017). Acute effects (e.g., short-term
memory, motor coordination, decision-making) and long-term consequences (e.g.,
cannabis use disorder, cognitive/physical impairments, induction or exacerbation of
paranoid ideation and psychotic symptoms) are associated with the use of Cannabis
sativa, a species of the plant (Volkow et al., 2014). The term cannabis refers to multiple
species of the plant (e.g., Cannabis sativa, Cannabis indica) that are distinguished by
varying amounts of the primary phytocannabinoid Δ9-tetrahydrocannabinol (THC) to
which the psychoactive effects of the plant have been attributed (Anthony et al., 2016;
Attard et al., 2018). Another naturally occurring cannabinoid found in Cannabis sativa is
cannabidiol (CBD), which was first identified as an inactive component of the plant in
1940 (Burstein, 2015). Though structurally similar to the partial endocannabinoid agonist
THC, CBD seems to function as an antagonist at CB1 and CB2 receptors with antiinflammatory responses linked to various disorders (e.g., anxiety, multiple sclerosis,
gastrointestinal imbalances, pain; Burstein, 2015; Pertwee, 2012). In recent years, there
has been renewed interest in research regarding the potential actions of CBD in the
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human body, particularly concerning its safety profile and potential moderating role for
endocannabinoid dynamics in the central nervous system (Bonaccorso et al., 2019).
Legal Status of Cannabis. In the United States, the legal status of cannabis
remains tenuous. Public interest in its potential properties and applications has been met
with suppression (e.g., taxation of product) as well as promotion (e.g., investment in
medical research) by governing bodies (Mead, 2019). Through the Controlled Substances
Act (CSA) of 1970, a federal statute regulating the sale, distribution, and use of narcotics
with abuse potential across medical and other contexts, the utilization of cannabis became
federally prohibited (Controlled Substances Act [CSA], 1970). Opposing regulations at
the state level have revitalized the potential for a cannabis industry as the CSA designates
federal preemption only in cases where state law poses a sufficient conflict of interest to
the enforcement of federal law (1970). As compared with other substances mentioned in
the CSA, federal agencies have not aggressively enforced the statute in response to
cannabis use and distribution (Mead, 2019). Multiple state laws have permitted the use of
cannabis for medical and recreational purposes based on increasing public initiatives for
decriminalization and legalization, beginning in 1996 with Proposition 215 in California
(Mead, 2019). 33 states currently permit medical applications of cannabis, and 13 states
allow for cannabis containing no more than their predetermined maximum percentage of
THC and no less than a minimum percentage of CBD content by weight to be used in
medical contexts (National Conference on State Legislatures [NCSL], 2020a, 2020b).
Legal Status of Cannabidiol. Though CBD is licit, this legal status is contingent
on multiple conditions. Until the passage of the 2018 Farm Bill, CBD was subject to
federal regulation as a resinous byproduct of cannabis plants containing known
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psychoactive compounds like THC (Cherney & Small, 2016; Mead, 2019; Potter, 2014).
However, this changed with the descheduling of hemp and its exemption from the
processing standards originally set by the CSA for cannabis. CBD products frequently
originate from cultivated hemp, which has been distinguished from other forms of
cannabis in the United States not by its own distinctive properties, but by nonintoxicating levels of THC content per plant (i.e., an internationally used and arbitrary
concentration of less than 0.3%; Cherney & Small, 2016; Mead, 2019). At the federal
level, hemp (i.e., non-psychoactive cannabis defined by low THC concentration) crop
was made commercially available provided that special conditions for licensed use and
analysis are met following the passage of the 2018 Farm Bill (Mead, 2019; Spindle et al.,
2019). CBD is presently legal by way of hemp as the source crop has been federally
authorized, though it remains a controlled substance if it is derived from a plant
containing more than 0.3% THC content.
The legal status of CBD has been compromised by inadequate scientific evidence
for its safety and effectiveness in human trials. The United States Food and Drug
Administration (FDA), which specified that licensed uses of hemp do not include the
manufacture of food or dietary products marketed as containing CBD, has expressed
concerns about the undefined properties and effects of CBD (Gottlieb, 2018; Mead, 2019;
USFDA, 2020a, 2020b). An FDA consumer update was published reaffirming this
decision, citing limited data on the safe usage of CBD and existing findings that indicate
health risks associated with its use (USFDA, 2020a). Nevertheless, CBD products are
marketed and sold by means of ambiguous labeling and minimal enforcement of quality
control standards (Mead, 2019; National Academies of Sciences, Engineering, and
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Medicine [NASEM], 2017; Ott, 2018; Seltenrich, 2019; Soleymanpour et al., 2021;
USFDA, 2017, 2020a). As a result, CBD is highly available in the natural products
market despite multiple administrative warnings.
Depending on the context, CBD may be categorized as a licit or illicit product,
which has hindered decisions being made about what conditions must be met for its legal
use (e.g., under what circumstances its use is likely to be harmful or benign) and the
enforcement of any relevant requirements. There are several barriers to the establishment
of clear regulatory controls for the sale of CBD products warranting consideration before
they may be enacted. Known issues bearing the greatest risk potential are quality control,
contamination, adverse effects, and the narrow scope of the evidence for or against CBD
use in various contexts.
Quality Control and Contamination. Whether obtaining CBD from low-THC or
THC-potent forms of cannabis, the Current Good Manufacturing Practices (CGMP) set
forth by the FDA require that crop sourcing and processing methods minimize
contamination and product inconsistency to maintain consumer safety (USFDA, 2017).
Sourcing from medical cannabis crops poses conflicts with federal requirements found in
the CSA about limits to THC content in cannabis, limiting communication between
cultivators and federal agencies about labeled contents due to possible penalties.
While the FDA is responsible for the regulation of CBD products, the process of
monitoring for extraction quality only takes place in response to unapproved usage of
CBD-focused labels for food or dietary products (USFDA, 2019). If a product has not
been identified as containing CBD due to misleading labeling, this action is not taken.
Quality control consequently becomes a responsibility of each state. State-level
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regulation varies profoundly in terms of the number and strictness of hemp-based product
restrictions, as well as the intensity of enforcement for these restrictions (NCSL, 2020b).
Currently, there are no unified standards for the analysis of the contents of general market
CBD products to certify dosage levels. This is an essential component of discerning how
CBD may be used in conventional medicine by defining a therapeutic dose, as well as
how consumer safety will be judged on an ongoing basis (Millar et al., 2019).
Cultivating CBD from an industrial hemp crop grown in fields used for other
agricultural purposes is efficient in terms of licensing and production as this type of hemp
crop is often used for fiber-based products as well (Attard et al., 2018; Cherney & Small,
2016). However, this method may increase the risk for contamination of CBD products.
Industrial hemp crops have been used to clean agricultural plots because they are highly
absorbent for harmful metals (e.g., lead, arsenic) and chemical contaminants (e.g.,
pesticides) that may otherwise pollute a field (Johnson, 2018; Russo, 2016b). THCcontaining commercial cannabis samples also possess excessive contaminant levels that
import significant health risks for consumers (Russo, 2016a). Though preventative
measures of careful site development and extraction methods could reasonably reduce
contaminant exposure, these measures have not been widely implemented by CBD
producers (Citti et al., 2019; Russo, 2016a, 2016b).
Adverse Effects. Adverse effects for CBD have been identified in clinical trials
as well as national data on e-cigarette or vaping product-associated lung injuries (EVALI;
Brown & Winterstein, 2019; Lozier et al., 2019). When smoked using an electronic
delivery system, CBD oil may contain additives, agents, or flavors linked to EVALI
symptoms of gastrointestinal distress, tiredness, and traditional symptoms of pneumonia
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(Chand et al., 2019). Of the nearly 2,300 reported cases of EVALI in the United States as
of December 2019, 1% reported the exclusive use of CBD-based products and 12% used
CBD products in conjunction with other e-cigarette or vaping products (Lozier et al.,
2019). In an analysis of clinical trials, approximately half of all participants endorsed
diarrhea, suppressed immunological responses, drowsiness, and exacerbation of hepatic
impairments as adverse effects associated with FDA-approved CBD-based interventions
(Brown & Winterstein, 2019). Potential drug-drug interactions based on CBD’s
pharmacokinetic (i.e., ways in which the drug is processed by the human body) and
pharmacodynamic (i.e., the effects of the drug on the human body) profiles were
identified that indicated a strong likelihood for changes in the metabolic processes
associated with CBD and other drugs (e.g., opioids, cardiological treatments, antifungals)
that impact their effectiveness and safety profiles. The dosage and route of administration
may moderate the risk for drug-drug interactions due to associated variations in half-life
and potency for CBD by form and method, such as longer lasting effects with smoking
and oral consumption (Millar et al., 2019).
The use of CBD may also adversely affect genetic and molecular processes. In a
cell culture model of adverse effects of CBD in humans, DNA damage (i.e., strand
breakage) and chromosomal disturbances evidenced by oxidation (i.e., destabilizing
electron losses from DNA in the process of chemical reactions) occurred (Russo et al.,
2019). Given that the levels of CBD used in the study are comparable to those in plasma
samples from CBD users, Russo and colleagues cautioned that cancer risks are likely to
be associated with CBD’s observed toxicity with genetic structures.
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Clinical Studies of Cannabidiol
At present, few studies of the effectiveness and safety of CBD for adults with
identified mental health conditions have been conducted, with anxiety and psychosis
being the focus of most randomized controlled trials (RCTs; Van Ameringen et al., 2019;
Black et al., 2019; Bonaccorso et al., 2019; Kirkland et al., 2022; Sarris et al., 2020).
Existing findings have been broadly categorized as preclinical and clinical.
Preclinical Findings. Advocates for CBD research have indicated that preclinical
findings are cause for a greater number of naturalistic studies of its effects on humans
(Fischer at al., 2015). Findings from trials of CBD dosage in mice indicate possible
anxiolytic properties, particularly for moderate injectable doses (Van Ameringen et al.,
2019; Blessing et al., 2015). This evidence is conflicting, however, as the availability of
THC or other cannabinoids may account for the anxiolytic effects that have been
attributed to CBD (Van Ameringen et al., 2019). Success in animal studies of CBD
treatment has not consistently predicted success in human trials (e.g., glycemic control
for diabetes; Jadoon et al., 2016, Rajesh et al., 2010). Given that preclinical studies in
behavioral medicine have been criticized as unreliable sources of evidence for the
enactment of human trials due to various methodological and translational weaknesses,
they have been excluded from the scope of this review (Pound et al., 2004; Shanks et al.,
2009).
Clinical Trials and Studies of Medical Conditions. Dravet syndrome, a severe
form of childhood epilepsy typically beginning in infancy, and Lennox-Gastaut syndrome
are the only FDA-approved clinical applications for CBD (Perucca, 2017). Though CBD
has been considered safe and effective in trials including children and adults with these
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forms of epilepsy (Silvestro et al., 2019), as well as efficacious by parents of children
with these conditions (Hussain et al., 2015), preliminary findings indicate that it may
decrease in efficacy over time via physical tolerance (Uliel-Sibony et al., 2018).
However, this finding was previously contradicted in at least one longitudinal case study
(Maa & Figi, 2014).
Typically used as an adjunctive therapy with THC, CBD has been evaluated as an
intervention for medical conditions (e.g., pain management) relevant to mental healthcare
due to the reciprocal relationship between psychiatric symptoms and physical illness in
adults (Allan et al., 2018; DiTomasso et al., 2009). CBD use has been possibly evidenced
in managing inflammation-linked side effects of chronic illnesses, though these effects
may be attributed to THC and not CBD (Allan et al., 2018). As compared with other
methods for pain management, CBD is considered as having a poor risk-benefit ratio.
Adverse effects of CBD use are clear for other medical conditions relevant to mental
status. For example, CBD is not recommended in the treatment of glaucoma, a condition
associated with neurocognitive decline (Diniz-Filho et al., 2017; Tomida et al., 2006).
CBD has been proposed for the treatment of viruses and chronic disorders thought
to be rooted in inflammatory responses (Mathur et al., 2020; Reznik et al., 2016). This
assumption is primarily based on lab studies of the inhibitory effects of CBD on
components of human cells involved in pro-inflammatory processes (e.g., cytokine or
chemokine production; Couch et al., 2017; Petrosino et al., 2018; Ruhl et al., 2018).
Inflammatory processes may influence the course of psychopathology at multiple stages,
and as such CBD’s anti-inflammatory properties may generate primary or secondary
mental health benefits, though no RCTs have been conducted on this topic (Martone,
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2019). Inflammation processes show consistent associations with anxiety-related
experiences in human participants according to a comprehensive review of neuroimaging
studies, which indicates a possible area of focus for future clinical trials evaluating the
use of CBD in the management of mental health-related symptoms (Felger, 2018).
Clinical Trials and Studies of Mental Disorders. The findings for the use of
CBD in the treatment of mental disorders are mixed due to methodological concerns and
the limited number of studies conducted. No contraindications have been established,
though CBD possesses the potential to interfere with dose-effectiveness for psychiatric
medications and exacerbate symptoms such as suicidal ideation based on its previously
reported side effects and chemical profile (Brown & Winterstein, 2019). CBD is
considered ineffective or minimally effective in the treatment of bipolar disorder (Zuardi
et al., 2010), Huntington’s disease (Consroe et al., 1991), Parkinson’s disease (Chagas et
al., 2014), and alcohol use disorder (Nona et al., 2019). Most human trials have focused
on schizophrenia and psychosis. According to a limited number of these trials, CBD use
may be linked to reductions in positive symptoms like hallucinations (Bhattacharyya,
Wilson, Allen, et al., 2018; Bhattacharyya, Wilson, Appiah-Kusi et al., 2018; Leweke et
al., 2012; McGuire et al., 2018). Other trials of CBD use for schizophrenia and psychotic
episodes have yielded few if any significant improvements in functional or assessmentbased outcomes (Boggs et al., 2018; O’Neill et al., 2018).
Case studies indicate potential reductions in relapse rates and abstinence for
adults with cannabis use disorders who were administered CBD (Crippa et al., 2013;
Shannon & Opila-Lehman, 2015). However, specific methods for assessing frequency,
duration, and quality of CBD administration were not present in at least one study, and
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single-case results cannot be reliably generalized to a population of interest. CBD
treatments may decrease cravings and frequency of cigarette use for tobacco users who
smoke (Morgan et al., 2013). Tobacco users may have lower interest in cigarette-relevant
cues with CBD treatments (Hindocha et al., 2018). A recent series of RCTs suggests that
cravings may be inhibited short-term in dependent opioid users who use CBD (Hurd et
al., 2015), and they may also experience longer-term inhibition of responsivity to heroinrelated cues (i.e., decreased anxiety and cravings after exposure; Hurd et al., 2019). A
caveat of the latter study was that these effects were present in controlled but not
naturalistic environments where cues are more likely to facilitate relapse.
Anxiety Disorders. There are few studies of the use of CBD for anxiety
disorders, even in the context of research on cannabis use (Van Ameringen et al., 2019).
Defining and measuring anxiety-related constructs and CBD interventions, as well as
ethical considerations (e.g., informed consent, participant safety) are some of the cited
methodological impediments for research on this topic (Leen-Feldner et al., 2021).
Existing studies have mostly small sample sizes based on predominantly healthy male
volunteers, which reduces the likelihood of generalizable outcomes (Skelley et al., 2020).
Though the data are limited, there is some empirical support for the use of CBD to treat
clinically significant anxiety. Medical marijuana users in multiple large-scale surveys
reported decreased levels of stress and anxiety regardless of how severe their anxiety
symptoms were, particularly when using products with more CBD content (Van
Ameringen et al., 2019). However, findings on these effects for medical marijuana users
may not be comparable to those for CBD-only users. Adults receiving treatment as usual
in an outpatient clinic endorsed sustained reductions in anxiety symptoms when engaging
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in concurrent CBD use (Shannon et al., 2019). Shannon and colleagues (2019)
acknowledged that patients at the sampling site frequently avoided using pharmaceutical
interventions for anxiety, which may have biased self-report ratings (Van Ameringen et
al., 2019). In a later study, this supposition was cited in the context of placebo effects.
Spinella and colleagues observed that participants with strong preexisting beliefs that
CBD reduced anxiety rated themselves as experiencing less anxiety when expecting to
receive hemp oil containing CBD versus a dose of CBD-free hemp oil, unaware that
neither dose contained CBD (Spinella et al., 2021).
Individuals with clinically significant social anxiety have endorsed significant
decreases in perceived anxiety with moderate doses of CBD, but not a placebo condition
(Crippa et al., 2011). CBD dosage and reductions in perceived anxiety appear to co-occur
with changes in cerebrovascular flow in paralimbic and limbic areas previously
associated with subjective anxiety that may mediate the relationship between CBD and
anxiety reduction (Crippa et al., 2004; Li et al., 2019; Skelley et al., 2020). In another
randomized controlled trial, Bergamaschi and colleagues (2011) found that individuals
with social anxiety who received CBD treatment experienced significant reductions in
negative self-perceptions and anxiety during a public speaking simulation relative to
other groups. The results of another single-condition trial of men who participated
simulated public speaking suggested that moderate doses of CBD significantly reduced
their subjective social anxiety ratings (Linares et al., 2019). In similar studies of healthy
volunteers, moderate doses of CBD also reduced anxiety levels following simulated
public speaking tests (Zuardi et al., 1993; Zuardi et al., 2017). Adults treated with CBD in
another study did not endorse reductions in anxiety based on social rejection, nor
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responsivity to negative emotional stimuli, suggesting that situational social anxiety may
not be affected by CBD use (Arndt & de Wit, 2017).
Beliefs about Treatment and Illness
The decision to use CAM is independently related individual beliefs regarding
treatment and illness (Bishop et al., 2006). Vincent and Furnham (1996) advanced the
terms push factors and pull factors for reasons that CAM users avoid conventional
medicine or might engage in the use of alternative practices. Push factors identified by
their sample of CAM users, such as ineffective treatment encounters and adverse effects
of conventional medicine, appear to align with large scale survey data on adult CAM
users in the United States (Jou & Johnson, 2016; Nahin et al., 2010; Vincent & Furnham,
1996). American adults who use CAM have reported an unmet need for more proactive
and collaborative dialogues about CAM usage initiated by conventional providers, which
may be a partial basis for their expressed dissatisfaction with conventional treatment (Jou
& Johnson, 2016). Pull factors include relatively greater accessibility, perceived
effectiveness, natural and holistic attributes, and desire to participate in treatment (Bishop
et al., 2006, 2007; Vincent & Furnham, 1996). CAM users place greater importance on
psychological well-being relative to conventional medicine consumers (Bishop et al.,
2006, 2007).
The importance of push and pull factors may vary according to CAM users’ levels
of interest in novel treatments, dissatisfaction with conventional medicine, and adherence
to beliefs that validate CAM use (Furnham & Kirkcaldy, 1996). National surveys and
smaller scale studies provide moderate support for this proposed subcategorization of
CAM users based on differences in their CAM use behaviors (e.g., level of collaboration
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with CAM or conventional provider, type of CAM chosen) as well as demographic and
belief-related variables (Bishop et al., 2006, 2007). Pull factors at the level of pro-CAM
beliefs, as opposed to novelty and push factors from conventional medicine, are the most
consistently associated with CAM usage overall (Bishop et al., 2006, 2007).
Herbal Supplements and Treatment Beliefs
Herbal supplement users endorse similar treatment beliefs to CAM users, with
pull factors regarding the benefits and amenable properties of herbal medicine predicting
use behaviors better than push factors (Welz et al., 2019). Beliefs in the benefits of
choosing more effective (i.e., positively experienced) and healthier (i.e., beneficial
because it is “natural” and assumed to have fewer side effects/risks) forms of medicine
have stronger relationships with herbal CAM use behaviors than push factors (Welz et
al., 2019). Per Welz and colleagues, individuals already using CAM gave higher
endorsements to these expectancies for herbal medicine use as compared to new users.
Familiarity and familial traditions may increase the likelihood of use, especially if
comparing established users to new users, though the generalizability of these culturelinked findings from a German sample to an American sample was uncertain.
Anxiety and Beliefs about Illness and Treatment
For individuals managing anxiety symptoms through CAM, their illness and
treatment-related beliefs appear to be congruent with those of other CAM and herbal
medicine users (Bishop et al., 2007; McIntyre, Saliba, Wiener, et al., 2015; McIntyre et
al., 2019). According to a model derived from the theory of planned behavior, controlrelated beliefs and anxiety symptom severity predict the intention to use herbal forms of
CAM as well as positive attitudes towards CAM usage (Ajzen, 1991; McIntyre et al.,
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2019). Beliefs in control over symptoms and health when taking herbal medicine predict
intentions to use herbal CAM to treat anxiety, which may also be attributed to pull factors
(i.e., fewer side effects, attribute of “naturalness”) and ease of access (McIntyre, Saliba,
& Moran, 2015; McIntyre, Saliba, Wiener, et al., 2015; McIntyre et al., 2019). The core
dilemma of perceived lack of control inherent to anxiety symptomatology may intensify
the importance of control beliefs (Barlow, 2015).
Symptom severity has consistently predicted the intention to use herbal
supplements, which pertains to belief content as aversion to risk and uncertainty increases
with symptom severity and reinforces attempts to self-treat with interventions deemed
safest based on perceived attributes (Bystritsky et al., 2012; McIntyre, Saliba, & Moran,
2015; McIntyre, Saliba, Wiener, et al., 2015; McIntyre et al., 2016; McIntyre et al., 2019;
Ravven et al., 2011). Naturalness is an attribute that herbal CAM users with anxiety have
associated with effectiveness and safety, particularly in the context of experiences such as
dissatisfaction with conventional medical encounters that function as push factors
(McIntyre, Saliba, & Moran, 2015; McIntyre, Saliba, Wiener, et al., 2015). It is possible
that push factors influence risk-benefit evaluations of conventional treatment and
perceptions of illness manageability. These factors should be considered considering the
aforementioned factors of symptom severity as well as control beliefs.
Subjective norms related to social approval are less predictive of the intent to use
herbal CAM for anxiety, which is consistent with the clinical hypothesis that anxiety
results in preoccupation with a subjective state (Barlow, 2016; McIntyre et al., 2019).
However, subjective norms based in familial traditions or behavioral precedent in one’s
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social group may be a source of influence warranting further investigation (Welz et al.,
2019).
Common-Sense Model of Self-Regulation
The Self-Regulatory Model of Illness (SRMI), currently termed the CommonSense Model of Self-Regulation (CSM), was selected to organize factors related to CAM
usage for generalized anxiety (Leventhal et al., 1992; Leventhal et al., 2016). This model
assumes that consumers using self-directed medical approaches to treatment employ
identifiable, predictable cognitive-behavioral processes in deciding their response to a
perceived threat to their health. The CSM presents an accommodating framework for the
primary mechanisms of generalized anxiety as its focal points of self-regulation and
managing unpredictability are important to those with anxiety disorders (Barlow, 2016).
In the CSM, self-regulatory processes are triggered by experiential and contextual
cues such as mass media, the opinions of others, or atypical somatic events (Leventhal et
al., 2016). Contextual cues have a reciprocal relationship with personal norms (i.e.,
prototypes; Schwartz, 1977) as well as mental representations of illness and treatment. In
the CSM, prototypes of one’s functioning (i.e., “being healthy” or “being sick”) are made
through identity (e.g., labels such as healthy, sick, able, disabled, etc.), a timeline (e.g.,
time of onset, duration, and decline for health status), consequences (i.e., potential or
actual outcomes), causes (i.e., what conditions, internal or external, create health status),
and control (i.e., self-efficacy as well as control of others over health or illness).
The same influential factors apply to representations of illness and treatment. For
anxiety, a representation of illness will consist of a label (e.g., anxiety, worry, nerves,
etc.), timelines, anticipated and actual outcomes, contributing causes, and perceptions of
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control. Corresponding perceptions of a treatment like CBD would be mentally
categorized according to what it is, expectancies for its effects, why it works, what it
treats, and how manageable it is as a form of treatment for that individual. These
perceptions frequently present as beliefs.
Finally, the CSM addresses behavior in the form of the action plan. Action plans
are behavioral responses and related expectations linked to environmental cues,
prototypes, mental models for illness and treatment, and broader subjective norms for
health status. Action plans include strategies for potential, current, and ongoing concerns
in the form of behavioral initiation as well as maintenance. This is pertinent to CAM and
anxiety in terms of responses to cognitive-affective events as well as behaviors that
change how anxiety is experienced (e.g., avoidance-based coping strategies; Cameron,
2003). Per Cameron, anxiety bears a bidirectional relationship in the CSM with
information processing and environment. This corresponds with existing hypotheses on
the synergetic relationships of context cues, fear, cognitive processing, and both affective
and behavioral responses in anxiety (Barlow, 2016; Cameron, 2003).
CSM components have multiple levels (i.e., behavioral, perceptual, and actual) that can
all influence how each one is managed. Therefore, the model is non-linear in nature, not
requiring specific degrees of influence or a procedural process for treatment belief
formation. In the context of the current study, several factors (i.e., demographic variables,
symptom severity, experiences with CAM, beliefs about illness and treatment,
perceptions of control) have exhibited varying degrees of reciprocal influence in prior
research on the decision to use CAM (Bishop et al., 2006; McIntyre et al., 2019; Ravven
et al., 2011). The CSM is appropriate for understanding these factors as multifaceted,
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dynamic influences on the decision to use an herbal form of CAM as a means of selfregulation. It has previously been applied to studies of CAM users, though the literature
on these applications is limited in volume (Bishop et al., 2005, 2006, 2008; Usher et al.,
2015).
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CHAPTER 3: METHOD
The purpose of the current study was to assess for potential differences in CAMrelated treatment beliefs for cannabidiol-using adults residing in the United States who
endorsed symptoms of generalized anxiety disorder as defined by the criteria set forth in
the DSM-5. A cross-sectional, between-groups design was used with an anonymous selfselecting sample according to CBD use status to obtain quasi-experimental and
observational data on these groups. The online survey in this study utilized mixed
methods as both existing quantitative scales and an exploratory question were presented.
An adapted form of the Complementary and Alternative Medicine Beliefs Inventory
(CAMBI; Bishop et al., 2005) measured treatment beliefs through a 17-item
questionnaire via a 7-point Likert scale to assess the level of endorsement for CAMrelated treatment beliefs in natural treatments, participation in treatment, and holistic
models of health. The Holistic Complementary and Alternative Medicine Questionnaire
(HCAMQ; Hyland et al., 2003) was used to measure beliefs about the scientific validity
of CAM through an 11-item questionnaire on a 6-point Likert scale. Respondents
answered dichotomous questions about the legal status of all drugs as well as nonprescription recreational use of cannabis. An exploratory question inquired about beliefs
respondents had about CBD being a cannabis derivative.
Participants
Participants recruited for this study were adults (i.e., 18 years of age or older)
residing in the United States who endorsed symptoms of generalized anxiety disorder.
Out of 330 respondents, 180 participants were acquired. The participant group was near
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equally divided for user and non-user groups. Demographics for participants have been
described in the results.
Inclusion and Exclusion Criteria
Eligible participants were 18 years of age or older and endorsed anxiety
symptomatology. Participants who endorsed THC and/or cannabis use in addition to
CBD were included in the user group. Adults who endorsed using CBD for conditions
other than GAD were included. Respondents who did not complete the survey or
appeared to be invalid responders (e.g., spammers, random responders, repeat
responders) were excluded. Respondents endorsing ages below 18 years were excluded.
Respondents under 18 years of age presented concerns potentially unique to their age,
such as neurodevelopmental differences or attitudes that are markedly dissimilar from
adults, which may have significantly influenced study results. Individuals who endorsed
neither lifetime prevalence nor current experiences of generalized anxiety symptoms
were excluded from the study.
Screening and Recruitment
Participants self-selected into the study by clicking through a hyperlink to an
online survey promoted on social networks (i.e., specific forums related to surveys or
CBD on Facebook user groups and subreddits) or electing to participate based on
recommendations from their own social network sources. Information about the study
was posted on Facebook via content-relevant user groups. Screening occurred
automatically within REDCap in the form of initial questions about the age and country
of residence for the participant. Participants were asked a dichotomous question
regarding lifetime prevalence for generalized anxiety at the start of the survey.
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Respondents who answered “no” to this question and failed to endorse generalized
anxiety on the Generalized Anxiety Disorder Scale 7 (GAD-7; Spitzer et al., 2006) were
not included in study.
Measures
All reported demographic data and survey responses were captured and organized
in REDCap.
Generalized Anxiety Disorder Scale 7
The GAD-7 (Spitzer et al., 2006) is a screening tool used to detect symptoms of
generalized anxiety disorder (GAD) based on self-reported symptoms from the past two
weeks. Its seven criteria are based on primary symptoms of GAD as defined by the DSM5 (American Psychiatric Association, 2013). These symptoms are presented on 4-point
Likert scales ranging from 0 (not at all) to 3 (nearly every day) and indicators of
symptom severity. Severity is considered in the form of mild (5-9 points), moderate (1014 points), and severe (15 or more points) ranges. Scores above 10 points are clinically
significant and warrant additional follow-up with a clinician. The GAD-7 has
demonstrated good internal reliability (α = .92) as well as test-retest (r = .83) reliability.
Its developers established criterion and construct validity in the form of professional
judgments, convergent and divergent measures of psychopathology, as well as functional
outcomes (e.g., level of healthcare service utilization; Spitzer et al., 2006). The GAD-7 is
externally valid overall, though it may undervalue symptom severity in specific groups
(Parkerson et al., 2015).
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The Holistic Complementary and Alternative Medicine Questionnaire
The HCAMQ (Hyland et al., 2003) was developed based on groups of British
conventional medicine users and CAM users. It uses a 6-point Likert scale from 1
(strongly disagree) to 6 (strongly agree) to assess the overall strength of pro-CAM
beliefs in two areas. It was selected for use as its items on scientific validity capture
beliefs associated with CAM use not captured by the CAMBI. Overall high scores have
been significantly associated with lower age, increased natural product use, and
decreased use of conventional painkillers. It possesses two subscales representing beliefs
in the validity of CAM and holistic health, respectively. Internal reliability was
established for the overall scale (α = .80), the validity subscale (α = .83), and the holistic
health subscale (α = .75). Significant group differences on the holistic health subscale
were not detected, nor was this subscale predictive of trends in antibiotic use as a form of
conventional medicine (Hyland et al., 2003). The construct validity of the measure has
been questioned as it may be significantly improved by eliminating two positively
worded items and reordering the remaining items into two subscales: beliefs about CAM
and holistic health (Kersten et al., 2011). There have been mixed findings regarding the
measure’s generalizability in a limited number of diverse populations (Fortier et al.,
2014; Ganasegeran et al., 2014; Izgu & Gok Metin, 2020).
Complementary and Alternative Medicine Beliefs Inventory
The CAMBI (Bishop et al., 2005) is a scaled measure of the strength of treatment beliefs
related to CAM normed on British CAM users. In the context of the current study, it was
used to assess the categorical content and relative strength of pro-CAM treatment beliefs
in an unstudied population (i.e., individuals using CBD for generalized anxiety). The
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CAMBI uses a 7-point Likert scale for 17 items on three subscales pertaining to treatment
beliefs and CAM. The subscales pertain to categories of treatment beliefs for CAM users
(i.e., natural treatments, holistic models of health, and participation in treatment) and
each subscale has either five (i.e., participation in treatment) or six (i.e., natural
treatments, holistic health) items. Ratings range from 1 (strongly disagree) through 4
(neither agree not disagree) and ending at 7 (strongly agree). Items with anti-CAM
content are reverse scored, and increased scores on the items indicate greater
endorsements for pro-CAM treatment beliefs associated with use.
Information on the reliability and validity of the CAMBI primarily comes from
the initial results published by its developers (Bishop et al., 2005). Internal reliability for
the distinct subscales of natural treatments (α = 0.75), holistic health (α = 0.73), and
participation in treatment (α = 0.68) pose concerns with the acceptability of the latter
subscale and the results of these scales may be interpreted with caution. The internal
consistency of the overall measure was acceptable (α = 0.81). Criterion validity for the
CAMBI was established through positive and significant intercorrelations between scores
on the CAMBI and reported CAM use (ρ = .39) as well as the three subscales, holistic
health correlating most strongly (ρ = .47). Convergent construct validity was established
through correlations between the CAMBI and HCAMQ (ρ = -.55). External validity has
been generally established in diverse patient and practitioner populations (Brewer et al.,
2019; Goldstein et al., 2015; Kuo et al., 2018) except for older adults in the United States
(Grzywacz et al., 2013).

TREATMENT-RELATED BELIEFS IN CANNABIDIOL USERS

35

Procedures
This study was conducted by a doctoral-level student in a clinical psychology
program based in the Eastern U.S. near a major city. Participants who followed the
hyperlink for the initial phase of the study were presented with screening prompts for
age, country of residence, and lifetime prevalence of core generalized anxiety symptoms
(e.g., “feeling anxious or on edge”, “becoming easily annoyed/irritable”) in a survey
hosted on REDCap. Respondents not over the age of 18 or residing outside of the United
States were thanked for their interest and informed they were excluded from participation
in the study. Those who met the age and location inclusion criteria were presented with a
summary of the study’s purpose (i.e., to share their views on CBD and its applications).
Following this review, respondents were presented with questions about initial
demographic information (i.e., gender, age, ethnicity, state of residence, income, and
educational levels). Respondents were asked if they had a confirmed diagnosis from a list
of common conditions potentially associated with CBD use based on results from a prior
cross-sectional online survey and national consumer survey of CBD users (Corroon &
Phillips, 2018; Gallup, 2019).
Questions were asked regarding current and/or prior use of CBD and behavioral
trends for personal use of CBD (i.e., route of administration, dosage, frequency,
progression of use, concurrent or primary use of cannabis). Equivalent questions were
asked about participants’ past and present trends for THC use. Respondents were
presented with the GAD-7, HCAMQ, and CAMBI questions in electronic format through
REDCap. Radio buttons were used for the ratings on the Likert scales, and both dropdown and check boxes were implemented where possible for demographic data.
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Participants had the option to answer two dichotomous yes-no prompts regarding the
legal status of recreational use of substances (i.e., “In my opinion, the personal use of all
drugs should be legal in the United States”; “In my opinion, the personal use of cannabis
without a prescription should be legal in the United States”). An open-ended text
response box was used for the exploratory question (i.e., “In your opinion, what are some
pluses and minuses about CBD being a cannabis-based product?”) with a 500-character
limit.
Respondents had the option to enter a $50 gift-card drawing from a selection of
major vendors (i.e., eBay, Amazon, Starbucks) by clicking through to a separate survey
not linked to the primary survey. They were asked to input their name and e-mail address.
This was done to help ensure participant privacy by separating the data of a respondent
from their identifiable entry into the drawing. Data were coded, stored, and protected
through the same program and analyzed in SPSS (for quantitative data) and ATLAS-ti
(for qualitative prompt) software.
Statistical and Data Analyses
Multiple forms of analysis were used for the cross-sectional, mixed-methods
study. Descriptive statistics were used to characterize the study sample. Mean
differences, standard deviations, and percentages related to demographic characteristics,
overall scores, and subscales of each measure were presented. Collected characteristics
included mean age, ethnicity, gender, income level, educational level, state of residence,
current and/or historic endorsement of generalized anxiety, current and/or prior
cannabidiol (CBD) use, current and/or prior cannabis use, current and/or prior other
forms of CAM use, and methods of use (i.e., for CBD and cannabis). Percentages were
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calculated for response frequencies on prompts about legalization for recreational
cannabis and all drug use in the United States.
Chi-square and independent samples t-tests were performed to assess for
significant differences between groups for demographic characteristics (i.e., age, gender,
level of education) as well as anxiety symptom severity as rated on the GAD-7. For
Hypotheses I, II, III, and IV, independent samples t-tests were used to examine whether
significant mean differences in scores on relevant subscales of the CAMBI and HCAMQ
existed between CBD and non-CBD user groups in the sample. These tests were
performed to examine the relationship between endorsements of CBD use for anxiety and
CAM-related treatment beliefs. Assumptions associated with the use of the independent
samples t-test that were evaluated included normality, homogeneity of variances, and
independence of groups and observations. Descriptive statistics (i.e., mean, standard
deviation, kurtosis, skewness) were reviewed to assess for normality in addition to
Kolmogorov-Smirnov and Shapiro-Wilk values. Homogeneity of variances were tested
via Levene’s test for equality of variance. Independence was established through
screening questions to distinguish the data of CBD users from non-CBD users.
Histograms and boxplots facilitated the identification of extreme scores in the dataset.
An open-ended qualitative prompt was used to gather belief content intended to
represent answers to the exploratory question regarding positive and negative perceptions
of the relationship between cannabis and CBD in different CBD user groups. Answers to
this question were exported into a text document. This content was subject to thematic
analysis (i.e., data reviewed, codes generated, subthemes assessed and defined for overall
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themes of “advantages” and “disadvantages”) based on Braun and Clark’s guidelines
(2006), as well as visualized using ATLAS.ti software.
Power Analysis
Differences for CBD user and non-CBD user group means on a two-tailed
independent measures t-test were assessed via post hoc power analysis. The analysis was
performed in G*Power assuming a 95% confidence interval with a 5% margin of error
(Faul, et al., 2007). Means and standard deviations for CBD and non-CBD users on the
Natural Treatments subscale of the CAMBI were entered given the significance of the
results of this hypothesis for the overall study and absence of a priori data for reference.
With these data, an effect size of d = 0.47 was determined. Statistical power exceeding
80% was achieved based on the values established above.
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CHAPTER 4: RESULTS
Participants
All participant recruitment took place online during July 2021. In total, 180 of
330 responses to the survey were complete and subsequently included in analyses. Of the
180 included participants, the majority identified as male (82.1%) and over half identified
as White (55.6%). The mean participant age was 30.8 years old (SD = 6.9). Most
participants had college-level degrees and reported annual earnings between $25,000 and
$100,000. The most reported comorbidities were sleep disorders (43.9%), depression
(42.8%), and chronic pain (38.3%). Substances most endorsed on a prompt regarding
active use by participants were cannabis (42.2%), alcohol (37.8%), and caffeine (34.4%).
Participant characteristics are in Tables 1 and 2.
For analyses, participants were divided into subgroups based on their responses to
questions about their CBD use. Those who never tried or tried but do not use CBD were
categorized as non-users. All other responders were categorized as CBD users. CBD
users (n = 94) did not significantly differ from non-users (n = 85, 1 participant CBD
status unknown) by age, t = -0.032, p = .74. User and non-user groups did not differ
significantly by gender, χ2 = .12, p = 0.73, or education level (i.e., GED/high school
diploma and above versus lower levels), χ2 = 3.22, p = 0.07. Participant age did not
significantly relate to any of the four study outcome scales, p > 0.05 for all.
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Table 1
Sociodemographic Characteristics of Survey Respondents (N = 180)
Variable

n

%

Age (years)

135

75

Identified gender
Male
Female
Third gender or non-binary

147
32
--

82.1
17.9
--

Race or ethnicity
Alaskan native or native American
Asian or pacific islander
Black or African American
Caucasian or White
Hispanic or Latinx
Multiracial
Other ethnicity not listed

14
34
25
100
11
---

7.8
18.9
13.9
55.6
6.1
---

4
12

2.3
6.9

56
39
52
10
1

32.2
22.4
29.9
5.6
0.6

Annual income
None
Less than $25,000
$25,000 to 49,999
$50,000 to 74,999
$75,000 to 99,999
$100,000 to 149,999
$150,000 or greater

1
11
51
65
40
7
2

0.6
6.2
28.8
36.7
22.6
4.0
1.1

Residential region
Midwest
Northeast
South
West

15
38
46
79

9
21
26
44

Highest level of education
No formal education
Formal education without high school
diploma or GED
High school diploma or GED
Technical or associate’s degree
Bachelor’s degree
Master’s degree
Doctorate

Note. Missing values were recorded for age (n = 45), gender (n = 1), highest level of education (n = 6),
annual income (n = 3), and residential region (n = 2) as responses were optional for these questions.
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Table 2
Comorbidities and Current Substance Use in Survey Respondents (N = 180)
Variable

N

%

Comorbidities
Depression
Chronic pain
Gastrointestinal disorder(s)
Thyroid disorder(s)
Sleep disorder(s)
None of these apply to me

77
69
50
24
79
15

42.8
38.3
27.8
13.3
43.9
8.3

Actively used substances a
Alcohol
Amphetamines
Caffeine
Cannabis
Cocaine
Crack
Ecstasy or molly
Fentanyl
Hallucinogens
Inhalants
Heroin
Methamphetamine
Oxycontin
PCP
Tobacco or nicotine vape
Xanax
Other

68
21
62
76
32
10
14
5
12
13
6
4
2
-49
2
1

37.8
11.7
34.4
42.2
17.8
5.6
7.8
2.8
6.7
7.2
3.3
2.2
1.1
-27.2
1.1
0.6

a

a

Percentages were based on the overall number of participants, not the number of responses, as participants

could select more than one response.
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THC and CBD Product Use
Approximately 44% of participants reported either trying but not currently using,
or never using THC (Table 3). Eighty-five participants reported never trying or trying and
not using CBD products (Table 4). Oral consumption and smoking or vaping were the
most common methods of use for both THC and CBD. Most THC-using participants
endorsed less than 7 grams of THC per use and no more than 10 milliliters for liquid
products. Nearly all CBD users endorsed less than 500 milligrams per use. About 78%
reported no change in the amount of THC and/or CBD used over time.
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Table 3
THC Use in Survey Respondents (N = 180)
Variable

N

%

Frequency of THC use
Never
Tried but don’t use
Less than once a month
1-3 times per month
Once a week
1-6 days per week
Daily
Multiple times per day

41
39
21
23
25
20
8
3

22.8
21.7
11.7
12.8
13.9
11.1
4.4
1.7

Method of THC use a
Topical oil/lotion/cream
Oral edibles
Oral pills/supplements
Oral drops or oil
Smoke with tobacco
Smoke without tobacco
Vape

1
38
41
29
34
13
5

0.6
21.1
22.8
16.1
18.9
7.2
2.8

Amount of THC per use
Less than 1 gram
Approximately 1 gram
Approximately 3-4 grams
7 grams
14 grams
28 grams
Over 28 grams

4
20
42
35
10
---

2.2
11.1
23.3
19.4
5.6
---

Amount of liquid THC per use a
1 to 10 milliliters
11 to 30 milliliters
31 to 50 milliliters
51 to 70 milliliters
71 to 90 milliliters
91 to 100 milliliters

36
9
8
2
-1

64.3
16.1
14.2
3.6
-1.8

Endorsed change in THC amount used b
Yes
No

38
140

21.3
78.7

a

Percentages were based on the overall number of participants, not the number of responses, as participants

could select more than one response.
b

Missing values were recorded for amount of THC used (n = 2) as responses were optional.
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Table 4
CBD Use in Survey Respondents (N = 180)
Variable

N

%

Frequency of CBD use
Never
Tried but don’t use
Less than once a month
1-3 times per month
Once a week
1-6 days per week
Daily
Multiple times per day

41
44
19
25
14
24
10
2

22.9
24.6
10.6
14.0
7.8
13.4
5.6
1.1

Method of CBD use
Topical oil/lotion/cream
Oral edibles
Oral pills/supplements
Oral drops or oil
Vape

2
42
40
26
24

1.1
23.3
22.2
14.4
13.3

Amount of CBD per use
1 to 100 milligrams
101 to 200 milligrams
201 to 300 milligrams
301 to 500 milligrams
501 to 1000 milligrams
Over 1000 milligrams
Don’t know

13
27
28
26
4
2
--

7.2
15.0
15.6
14.4
2.2
1.1
--

39
141

21.7
78.3

41
44
19
25
14
24
10
2

22.9
24.6
10.6
14.0
7.8
13.4
5.6
1.1

Endorsed change in CBD amount used
Yes
No
Frequency of CBD use
Never
Tried but don’t use
Less than once a month
1-3 times per month
Once a week
1-6 days per week
Daily
Multiple times per day

Note. Missing value was recorded for frequency of CBD use (n = 1) as responses were optional.
Percentages for the method and amount of CBD use were based on the overall number of participants, not
the number of responses, as participants could select more than one response.
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Anxiety Severity
Participants endorsed a full range of scores on the Generalized Anxiety Disorder7 (GAD-7) Scale, with a minimum score of 0 and maximum score of 21. The mean
participant score on the measure was 9.2 (SD = 4.4), which falls between the Mild to
Moderate anxiety level range (Table 5). CBD users (n = 94) reported significantly greater
GAD scores (M = 11.01, SD = 3.36) compared to non-users (n = 85, M = 7.38, SD =
4.60), t(177) = -6.08, p < .001. T-test results were confirmed to be significant with
a Mann-Whitney U test, p < .001.

Table 5
Mean Generalized Anxiety Disorder-7 Responses (N = 180)
Scale
GAD-7

M

SD

9.24

4.41

Opinions about Substance Use Legalization in the United States
Most participants endorsed support of both the legalization of all drugs (n = 132)
and cannabis (n = 129) for personal use in the United States (Table 6).

Table 6
Frequencies for Beliefs about Legal Status of Substances in the United States (N = 180)
Beliefs

n

%

Personal use of all drugs
Legalize
132
74.2
Do not legalize
46
25.8
Recreational use of cannabis
Legalize
129
72.5
Do not legalize
49
27.5
Note. Missing values were recorded for the first (n = 2) and second prompt (n = 2) as responses were
optional for both questions.
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Outcomes and Assumptions
Prior to conducting independent samples t-tests (CBD versus non-CBD users),
assumptions were assessed. Analyses indicated that outcome variables significantly
deviated from a normal distribution (Table 7).

Table 7
Tests of Normality for the Complementary and Alternative Medicine Beliefs Inventory and Holistic
Complementary and Alternative Medicine Questionnaire
Subscale

Kolmogorov-Smirnov
Statistic

df

Sig.

Shapiro-Wilk
Statistic

df

Sig.

CAMBI
Holistic Health
Natural Treatments
Participation in Treatment

.114
.100
.141

122
122
122

.001
.005
.000

.956
.978
.848

122
122
122

.000
.043
.000

HCAMQ
Scientific Validity

.101

180

.000

.957

180

.000

Due to deviation from a normal distribution for resulting data, significant findings
from parametric tests were confirmed by utilizing a nonparametric Mann-Whitney U test.
On the Holistic Health subscale of the CAMBI, most participants endorsed scores
between 15 and 25 with a maximum possible score of 35 (M = 20.23, SD = 2.86). The
average score for all participants who completed the Natural Treatments subscale was
approximately 23 out of a maximum possible score of 42. Across participants who
completed the subscale of Participation in Treatment, the average score was
approximately 16 out of a maximum possible score of 35. Most participants endorsed
scores between 20 and 25 with a maximum possible score of 36 (M = 22.23, SD = 2.38)
on the Scientific Validity subscale of the HCAMQ. Respective means and standard
deviations for these scales are listed in Table 8.
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Table 8
Mean Scores for the Complementary and Alternative Medicine Beliefs Inventory and Holistic
Complementary and Alternative Medicine Questionnaire (N = 180)
Subscale

M

SD

CAMBI
Holistic Health
Natural Treatments
Participation in Treatment

20.99
25.27
16.09

3.38
5.65
2.38

HCAMQ
Scientific Validity

22.23

2.38

Note. Missing values were recorded for participant responses to the Holistic Health (n = 30) and
Participation in Treatment (n = 51) subscales.

Hypothesis I
The primary hypothesis that CBD users would endorse significantly stronger
beliefs in the scientific validity of CAM as compared with non-users was not supported
as CBD users did not endorse significantly higher scores on the Scientific Validity
subscale as compared with non-CBD users, t(150.61) = 1.70, p = .091, Table 9.

Table 9
Subscale Score Differences by User Group
Subscale

CAMBI
Holistic Health
Natural Treatments
Participation in
Treatment
HCAMQ
Scientific Validity

CBD users

Non-users

df

t

P

M

SD

M

SD

21.06
26.45
16.11

3.29
4.56
2.07

20.92
23.83
16.06

3.48
6.31
2.71

148
151.57
127

-0.26
3.15
-0.11

.792
.001
.907

21.96

1.94

22.57

2.72

150.61

1.70

.091

Note. Equal variances were assumed for analyses of Holistic Health and Participation in Treatment data.
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Hypothesis II
The second hypothesis, that CBD users would report stronger beliefs in the
importance of holistic properties of CAM than non-users was not supported. Specifically,
no significant difference in scores between CBD-user and non-user groups was found on
ratings of Holistic Health, t(148) = -0.26, p = .792, Table 9.
Hypothesis III
The hypothesis that CBD users would hold stronger beliefs in favor of natural
treatment than non-users was supported in the anticipated direction. There was a
significant difference in scores between CBD using (M = 26.45, SD = 4.56) and nonusing (M = 23.83, SD = 6.31) groups on ratings of Natural Treatments, t(151.57) = 3.15,
p = .002, Table 9. A subsequent Mann-Whitney U test confirmed that these results were
significant, p = .001.
Hypothesis IV
The final hypothesis that CBD users would endorse stronger beliefs than nonusers in the importance of being actively involved in their treatment was not supported as
no significant difference in scores on the Participation in Treatment subscale was found
between groups, t(127) = -0.11, p = .907, Table 9.
Beliefs about Relationship to Cannabis
In total, 70 independent responses to the open-ended question at the end of the
survey were identified and exported into a text file. This file was imported into ATLAS.ti
software for thematic analysis. After labeling words and phrases associated with common
concepts found in prior research on beliefs about CAM, data were placed into conceptual
groups. Thematic groups and frequencies are listed in Table 10.
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Table 10
Content from Respondent Beliefs about Cannabidiol being a Cannabis Derivative
Subthemes
Advantages
Accessible

Effective/Efficacious

Natural
Safe

Disadvantages
Costly

Harmful

Illicit association

No Difference

Example quote

N

%

“You can buy CBD …
legally”
“Can be used internally
and externally”
“Convenient”
“Effective in treating
anxiety”
“Can be used medically”
“Therapeutic”
“It’s 100% natural”
“It’s natural”
“No hallucinogenic
effect”
“Non-addictive”

6

8.6

53

75.7

3

4.3

11

15.7

4

5.7

45

64.3

5

7.1

1

1.4

“Expensive”
“Not easy to buy”
“Not easy to purchase”
“Significant side effects”
“Addictive”
“Creates dependence”
“Hurts appetite”
“Compounds from
cannabis can cause
intoxication”
“Negatively associated in
society with illegal use”
“People think I’m getting
high”
“I don’t think they are
fundamentally
different”

Note. The full text of the open-ended prompt was, “In your opinion, what are some pluses and minuses
about CBD being a cannabis-based product?”.
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CHAPTER 5: DISCUSSION
This study compared CAM-related treatment beliefs in individuals experiencing
generalized anxiety who engaged in or denied CBD use. Existing data suggest that
American adults have increased use of herbal supplements such as cannabidiol (CBD) for
anxiety despite safety warnings and possible adverse effects (Brown & Winterstein,
2019; USFDA, 2020a, 2020b). Treatment-related beliefs concerning complementary and
alternative medicine (CAM) may motivate CBD use in this population. Researchers have
previously hypothesized that access, control, and satisfaction with treatment motivate
individuals with anxiety to use herbal forms of CAM (McIntyre, Sarris, & Moran, 2015;
McIntyre, Sarris, Wiener, et al., 2015). The purpose of this study was to gain a better
understanding of the similarities and discrepancies between treatment-related beliefs in
CBD users relative to non-users with anxiety.
Demographically, CBD users in this study were comparable to non-users in terms
of their level of education, gender, and age. CBD users reported significantly higher
clinical ratings of generalized anxiety symptoms than non-users. Most CBD users
reported oral use or smoking for routes of administration. Overall, participants from both
user groups reported support for the legalization of recreational cannabis and other
substance use in the United States. Based on prior studies of herbal medicine and general
CAM users, multiple hypotheses regarding the strength of beliefs potentially implicated
in using a form of CAM as treatment were explored (Bishop et al., 2006; McIntyre,
Sarris, Wiener, et al., 2015).
The first hypothesis of the study was that individuals who chose CBD in the
treatment of generalized anxiety would endorse stronger beliefs in the scientific validity
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of CAM as compared with non-CBD users. The results indicated that this hypothesis was
not supported. The second and fourth hypotheses that beliefs regarding holistic properties
of CAM and participation in one’s own treatment would be stronger for CBD users than
non-users were likewise not supported. The third hypothesis regarding CBD users having
significantly stronger beliefs in the importance of natural treatment when compared with
non-users was supported. Lastly, participants reported information about their beliefs
about advantages and disadvantages of CBD being a cannabis derivative, as well as
whether they endorsed the legalization of recreational cannabis and other substance use in
the United States. This provided information about what concepts individuals who
experience generalized anxiety associate with CBD and cannabis use.
Interpretation and Implications
The trends for descriptive characteristics gathered in this study were partially
consistent with previously reported demographics for individuals with anxiety and CAM
users (American Psychiatric Association, 2013; Asnaani et al., 2010; Bandelow &
Michaelis, 2015; Bishop et al., 2006; Committee on the Use of Complementary and
Alternative Medicine by the American Public, 2005; Green et al., 2017; Upchurch &
Rainisch, 2015). Specially, respondents were mostly White and middle-aged as
anticipated, yet more participants identified as male and had lower reported annual
income than expected. No characteristic-based distinctions were found between user and
non-user groups. While CAM users may have sorted into either the CBD user or non-user
group, these results are indicative of differences in demographic trends for individuals
who self-treat anxiety with CBD in the United States as compared with general CAM
users and those who experience anxiety. One interpretation of these findings is that CBD
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users represent a specific subpopulation of CAM users that does not reflect an overall
trend towards female herbal supplement users (McIntyre, Saliba, Wiener, et al., 2015),
which could reflect greater number of male than female cannabis users in the United
States (NASEM, 2017). This study’s sample may have also been affected by the
predominantly male demographic on Reddit forums observed in a national poll of social
media users in the United States given that Facebook group users are predominantly
female (Auxier & Anderson, 2021). In the context of the Common-Sense Model of SelfRegulation (CSM; Leventhal et al., 1992; Leventhal et al., 2016), gender identity and
level of income may be influential factors in the choice to use CBD over other forms of
CAM, though this claim requires further investigation. Healthcare professionals may
wish to add specific questions about CBD use to patient questionnaires as CBD users
may not consider themselves members of general CAM groups. Evidence that CBD users
preferred to consume oral products or smoke may be valuable in practice as mental
healthcare providers and general practitioners inquiring about CAM use can ask
clarifying questions to help identify CBD users (e.g., if endorsing a positive history of
smoking, ask about products used).
One result from the study merits comment, as CBD users endorsed significantly
greater levels of generalized anxiety than non-users. In previous literature, symptom
severity has predicted the intention to use herbal supplements, a trend speculated to stem
from avoidance of interventions perceived as riskier in favor of self-administered options
(Bystritsky et al., 2012; McIntyre, Saliba, & Moran, 2015; McIntyre, Saliba, Wiener, et
al., 2015; McIntyre et al., 2016; McIntyre et al., 2019; Ravven et al., 2011). The CSM
may account for this finding as indicative of weaker control beliefs or stronger prototypes
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for perceptions of personal illness. This suggests that at the level of behavior, CBD users
with anxiety may seek ways to manage symptoms by external means (i.e., by taking a
form of tangible treatment they may attribute control over their well-being to, as opposed
to modifying cognitions of self or symptoms). Mental healthcare providers may
incorporate this finding into their practice by addressing avoidance-based behaviors,
given that anxiety symptoms may be functionally reinforced by them, and that addressing
perceptions of self-efficacy may facilitate symptom relief.
Past researchers have found that CAM users are more concerned with pull factors
such as treatment being holistic, a desire to participate in treatment, accessibility of
interventions, and perceived effectiveness than non-users (Bishop et al., 2006, 2007;
Vincent & Furnham, 1996). The present study showed that a subpopulation of CAM
users who use CBD may place greater relative importance on the pull factor of choosing
natural treatment interventions as compared with other motivations to use CAM.
However, concepts affiliated with other factors were present throughout free responses
entered by participants (e.g., accessibility, effectiveness), suggesting relevant beliefs were
perhaps present but not captured by the structured measures used. As expected, push
factors were rarely identified in the responses to the open-ended prompt asking for
advantages and disadvantages of CBD’s relationship to cannabis as consistent with
previous literature on pro-CAM beliefs and herbal supplement users (Bishop et al., 2006,
2007; Welz et al., 2019).
The results of this research provide supporting evidence that the pull factor of
perceived “naturalness” may be a source of influence in forming the intent to use CBD to
treat anxiety for CBD users. Participants in this study expressed belief content suggesting
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that accessibility and effectiveness may be assumed attributes for CBD for individuals
experiencing anxiety. Individuals who experience anxiety and have beliefs related to
controlling their own health are more likely to use herbal CAM, meaning that belief
content expressed in the current study was consistent with previous findings about herbal
CAM users self-treating anxiety (McIntyre, Saliba, & Moran, 2015; McIntyre, Saliba,
Wiener, et al., 2015; McIntyre et al., 2019). Interestingly, herbal CAM users connotated
naturalness with effectiveness and safety in prior research, and these attributes were
frequently referred to by respondents in response to the final question of the study
(McIntyre, Saliba, & Moran, 2015; McIntyre, Saliba, Wiener, et al., 2015). Definitions of
these attributes may be shaped by dissatisfying encounters with traditional medicine.
Though participation in treatment was not valued more strongly by CBD users than nonusers in the current study, push factors may have latently influenced appraisals of risk
and benefits of conventional medicine. Higher ratings for anxiety symptoms may have
also been related to perceptions that conventional forms of treatment were previously
ineffective, though the results of the current study did not establish this directly. The
finding that most participants supported legalization of recreational use of cannabis
without a prescription implied a corresponding preference for uncontrolled, selfadministered use of cannabis products.
The CSM accounts for belief content endorsed by participants as a reciprocal
influence on the decision to use CBD (Leventhal et al., 1992; Leventhal et al., 2016).
Representations of treatment are based on defining what the treatment is or is not,
probabilities of what it will or will not do as a treatment, attributions of what causes it to
work and under what conditions, and how well the individual can control its use. Bearing
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in mind their higher anxiety symptom severity ratings, descriptive characteristics, and
reported use behaviors, CBD users in this study may have determined that as a natural
product CBD is safe, effective, complementary to conventional medicine, and highly
controllable. By using it more frequently, use behavior may strengthen assumptions that
CBD use is essential to processes of self-regulation. For healthcare professionals
interacting with CBD users, incorporating these findings into practice might involve
conversations about treatments that users may perceive as natural, easy to access, safe,
and effective from a list of complementary approaches that enhance processes of selfregulation (e.g., somatic awareness exercises).
Strengths and Limitations
Strengths of this study are its addition to a limited body of literature and novel
investigation regarding the treatment-related beliefs of those who use CBD as a form of
CAM. The qualitative prompt used in the study captured the perceptions of individuals
who have experienced generalized anxiety on the topic of CBD being a cannabis-derived
product, which informs both CBD and cannabis-focused research in the form of thematic
content on this topic. CBD users represent an increasing yet understudied population that
remains undefined in terms of descriptive characteristics, which were obtained in the
present study. Their similarities to previously studied CAM user groups contribute to the
general study of CAM users. Their differences further questions about whether CBD is a
form of CAM, and why their belief content may vary. Using the framework of CAM to
understand trends of use for a specific product (i.e., CBD) for generalized anxiety
provided existing measures, factor structures, models, and data that may be applied to
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ongoing explorations of CBD use. This information can be used to inform how CBD
users are categorized in future studies of their beliefs and use behaviors.
The present study had multiple limitations. The use of a cross-sectional and
single-phase online design did not allow for comparative conditions (e.g., pre- and postCBD use phases) or follow-up questioning, rendering the results exploratory and
descriptive. Participants self-selected into the study and thus the participant selection
could not be randomized. The questionnaires used were designed to target general users
or non-users of CAM and had not been previously used in groups of CBD or cannabis
users. Additionally, the predominantly male sample identified in this study is not
reflective of the anticipated female demographic previously linked to intent to use herbal
CAM for anxiety (McIntyre, Saliba, Wiener, et al., 2015). Due to these factors, the
generalizability of the sample used in this study to the general population remains
uncertain. Use of other forms of CAM in comparison groups was not accounted for that
may have influenced reported belief content for non-CBD users. All data were collected
through self-report without a secondary means of corroborating reported statuses due to
the anonymized online design, rendering results vulnerable to issues such as response
bias. Quality control of the CBD or THC cannabis products being used by participants
could not be assessed as respondents reported on their private use of commercially
available products with varying standards for purity.
Future Directions
Increased interest in and reported use of supplement-based complementary and
alternative medicine (CAM) such as cannabidiol (CBD) for adults in the United States
have not been matched by an increase in general research on what CBD users know and
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believe about mental health and treatment. Identifying potential predictors and
maintaining factors for CBD use through other forms of research may contribute to an
evidentiary base of information for consumers and providers. Human trials involving
CBD use, particularly multiphasic studies, would also better establish its safety profile
and potentially anxiolytic actions. Studies employing larger, more diverse samples may
also enhance the state of research regarding CBD.
The results of the present study may be advanced through inquiries about what
participants use in terms of conventional treatments for anxiety symptoms such as forms
of psychotherapy and prescribed medications used in conjunction with forms of
complementary medicine. Exploring this topic further serves to inform our knowledge of
how experiences with conventional medicine affect the decision to use CBD. An analysis
of data like those collected for the present study may reveal differences in cannabisassociated belief content by user group. Qualitative interviews with users and non-users
may provide greater detail about how individuals with generalized anxiety obtain
information, their perceptions of CBD as a form of conventional medicine or CAM, and
what the construct of naturalness connotes.
An opportunity to enhance the evidentiary base for this study would be the
qualitative development of scales specific to content of beliefs, attitudes, and experiences
of CAM users seeking to treat generalized anxiety symptoms. Few existing measures of
CAM-related beliefs and attitudes have been developed, and of these measures none
specifically address users seeking to manage anxiety symptoms (McIntyre, Sarris,
Wiener, et al., 2015). Moreover, existing tools seem to possess substantial developmental
flaws (e.g., lacking a pilot phase, insufficient rationale for item content, lack of a
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grounding theoretical model). Turning the focus of scale development towards the
appraisal of cognitive styles and errors (e.g., logical errors derived from inaccurate
sources of health literacy) as opposed to associational demographic variables has been
proposed as a stronger predictor of CAM use (Lindeman, 2011). This has the potential to
partially address issues of underutilization and underreporting in this population
(Bandelow & Michaelis, 2015).
Although the results of the present study call for further substantiation in future
studies, the findings are indicative of opportunities to improve mental healthcare as well
as general healthcare practice now through changing patient-provider dialogues. This
research serves to start these conversations about the ambiguities of CBD use and user
views about the importance of attributes like naturalness in treating anxiety in the
absence of adequate evidence for its categorization as a form of conventional medicine.
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